Opendata, web and dolomites

COSYN SIGNED

Comorbidity and Synapse Biology in Clinically Overlapping Psychiatric Disorders

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 COSYN project word cloud

Explore the words cloud of the COSYN project. It provides you a very rough idea of what is the project "COSYN" about.

clue    refine    comorbidities    molecular    crossover    models    intellectual    recommend    id    reproducibly    capitalise    disease    blinded    standard    clinic    genome    biology    vitro    place    unravel    outstanding    cosyn    alterations    approved    academic    scaled    symptom    correct    industry    personalised    intensive    decoding    rare    elucidate    comorbidity    diagnostic    neurons    extensive    cells    bench    precision    overlap    utility    pharma    assays    neurobiology    clinician    subtypes    technologies    therapeutics    integrates    samples    variants    cellular    discriminate    patients    neuroscience    editing    genomic    schizophrenia    synapses    classification    medication    criteria    autism    multiple    carefully    medicine    synaptic    screening    platforms    disability    patient    bedside    ameliorated    cell    precisely    clinical    indicated    compound    understand    double    genetic    generate    syndrome    dysfunction    effect    neurobiological    create    person    tools    mechanisms    neuronal   

Project "COSYN" data sheet

The following table provides information about the project.

Coordinator
KAROLINSKA INSTITUTET 

Organization address
address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177
website: www.ki.se

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://www.cosyn-precisionmedicine.eu
 Total cost 6˙000˙000 €
 EC max contribution 5˙925˙000 € (99%)
 Programme 1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
 Code Call H2020-PHC-2015-two-stage
 Funding Scheme RIA
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET SE (STOCKHOLM) coordinator 675˙000.00
2    STICHTING VU NL (AMSTERDAM) participant 1˙925˙000.00
3    MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV DE (MUENCHEN) participant 800˙000.00
4    SYNAPTOLOGICS BV NL (AMSTERDAM) participant 650˙000.00
5    UNIVERSITATSKLINIKUM BONN DE (BONN) participant 600˙000.00
6    LIFE AND BRAIN GMBH DE (BONN) participant 300˙000.00
7    CARDIFF UNIVERSITY UK (CARDIFF) participant 225˙000.00
8    HELSINGIN YLIOPISTO FI (HELSINGIN YLIOPISTO) participant 225˙000.00
9    INSTITUT PASTEUR FR (PARIS CEDEX 15) participant 225˙000.00
10    CEGAT GMBH DE (TUBINGEN) participant 100˙000.00
11    H. LUNDBECK AS DK (VALBY) participant 75˙000.00
12    REGION HOVEDSTADEN DK (HILLEROD) participant 75˙000.00
13    VERENIGING SAMENWERKENDE OUDER- EN PATIENTENORGANISATIES NL (SOEST) participant 50˙000.00
14    F. HOFFMANN-LA ROCHE AG CH (BASEL) participant 0.00

Map

 Project objective

COSYN integrates outstanding European academic and three large Pharma to exploit genomic findings for intellectual disability (ID), autism, and schizophrenia. We capitalise on comorbidity, from clinic to cells and synapses, and have access to large existing samples. We focus on rare genetic variants of strong effect in patients with clinical comorbidity. Our aims are: (1) Understand comorbidity by comparing symptom and syndrome overlap with novel neurobiological criteria; (2) Elucidate mechanisms of comorbidity using neurobiology for the major genomic clue of synaptic dysfunction to unravel the cellular mechanisms of comorbidity; (3) Generate novel neuronal cell models by using advanced technologies to make neurons from carefully selected patients, and use genome editing to create or correct genetic variants. Multiple advanced neuroscience platforms are in place to evaluate an extensive set of molecular and cellular parameters, and to identify alterations in synaptic biology characteristic of ID, autism, and schizophrenia. These cellular models will, with Pharma partners, be up-scaled to provide “industry-standard” cellular assays for compound screening; (4) Refine diagnostic tools, use novel genomic and cellular features to improve disease classification and discriminate specific patient subtypes; and (5) Case studies in precision medicine: with Pharma partners, identify patients with a genetic change whose consequences can be reproducibly ameliorated in vitro by an approved medication. Recommend to the patient and clinician a double-blinded, N-of-one crossover case study to evaluate the clinical utility of a medication precisely indicated for that person. COSYN is an integrated, state-of-art, bench-to-bedside programme focused on personalised therapeutics. COSYN is a crucial next step in “decoding” the genetic findings via intensive focus on the clinical and molecular comorbidities of ID, autism, and schizophrenia.

 Deliverables

List of deliverables.
Outreach activities (debate) on the philosophy of using patient-own cells for a new generation of cellular models Documents, reports 2020-04-09 09:39:17

Take a look to the deliverables list in detail:  detailed list of COSYN deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COSYN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "COSYN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.1.)

DECISION (2020)

DECOMPENSATED CIRRHOSIS: IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEMS APPROACHES

Read More  

OBERON (2019)

An integrative strategy of testing systems for identification of EDs related to metabolic disorders

Read More  

BIND (2020)

Brain Involvement iN Dystrophinopathies

Read More